You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
The hepatitis C virus (HCV) infects some 170 million people worldwide--more than four times as many as HIV--and is causing rising rates of liver disease. Like HIV, it is a wily foe for researchers developing drugs and vaccines, because HCV also mutates rapidly, creating a swarm of different viruses in each infected person that can thwart antibodies easily. But progress is beginning to be made: Although to date no one has been able to grow HCV reliably in a laboratory culture of cells, on page 110, researchers describe a new system for culturing HCV's RNA. And a study on page 107 offers one possible explanation for why some HCV strains are more resistant to interferon, the standard treatment for HCV, than others.
